Pregnancy outcomes of GLP-1 exposure in the first trimester
Apollo (University of Cambridge) · 07.09.2026
DOI: 10.17863/cam.134097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Apollo (University of Cambridge), erschienen am 07.09.2026. Verfasst von Laura Dearden und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP1-RAs), including semaglutide and dual incretin agonist tirzepatide, are now being obtained privately by people with or without pre-existing diabetes in the UK and elsewhere for weight management. In England, women of reproductive age account for roughly two in five of the 1.4 million people living with a BMI ≥ 40 kg/m2, suggesting they may be primary users of new weight loss drugs (1-3).
Schlagwörter
Zitieren
APA
Dearden, L., & Ozanne, S. E. (2026). Pregnancy outcomes of GLP-1 exposure in the first trimester. Apollo (University of Cambridge). https://doi.org/10.17863/cam.134097
Vancouver
Dearden L, Ozanne SE. Pregnancy outcomes of GLP-1 exposure in the first trimester. Apollo (University of Cambridge). 2026. doi:10.17863/cam.134097
BibTeX
@article{Dearden2026,
author = {Dearden, Laura and Ozanne, Susan Elizabeth},
title = {Pregnancy outcomes of GLP-1 exposure in the first trimester},
journal = {Apollo (University of Cambridge)},
year = {2026},
doi = {10.17863/cam.134097}
}
EUVIMED